Baseline characteristics of Daily Trial participants with vitamin C measures | ||||||
---|---|---|---|---|---|---|
 | All (N = 44) | Conventional Hemodialysis (N = 20) | Frequent Hemodialysis (N = 24) | |||
Characteristic | N Missing | mean +/-SD | N Missing | a | N Missing | a |
Age (yrs.) | 0 | 49.6 ± 12.1 | 0 | 50.6 ± 11.9 | 0 | 48.8 ± 12.4 |
Female sex (%) | 0 | 16 (36%) | 0 | 7 (35%) | 0 | 9 (38%) |
Hispanic ethnicity (%) | 2 | 12 (29%) | 2 | 3 (17%) | 0 | 9 (38%) |
Race | 0 | Â | 0 | Â | 0 | Â |
    Black White Native American |  | 28 (64%) |  | 14 (70%) |  | .14 (58%) |
    Aboriginal Canadian |  | 4 (9%) |  | 0 |  | 4 (17%) |
    Alaskan Native |  | 3 (7%) |  | 2 (10%) |  | 1 (4%) |
    First Nation Asian Native Hawaiian |  | 2 (5%) |  | 1 (5%) |  | 1 (4%) |
    Other Pacific Islander |  | 1 (2%) |  | 1 (5%) |  | 0 |
    Other/mixed/unknown |  | 6 (14%) |  | 2 (10%) |  | 4 (17%) |
Duration of end-stage renal disease (%) < 2 yr. 2–5 yr. > 5 yr | 11 | .12 (36%) 15 (45%) 6 (18%) | 4 | .7 (44%) 9 (56%) 0 | 7 | .5 (29%) 6 (35%) 6 (35%) |
Diabetes (%) | 0 | 13 (30%) | 0 | 6 (30%) | 0 | 7 (29%) |
Residual kidney function (%) Anuria > 0 to 1 ml/min > 1 to 3 ml/min | 0 | .26 (59%) 9 (20%) 9 (20%) | 0 | .6 (30%) 5 (25%) 9 (45%) | 0 | .20 (83%) 4 (17%) 0 |
Equilibrated per session Kt/V urea | 0 | 1.44 ± 0.20 | 0 | 1.46 ± 0.22 | 0 | 1.43 ± 0.19 |
Predialysis albumin (g/dL) | 0 | 4.12 ± 0.34 | 0 | 4.15 ± 0.36 | 0 | 4.09 ± 0.32 |
Predialysis sodium (mEq/L) | 0 | 139 ± 3 | 0 | 140 ± 3 | 0 | 139 ± 3 |
Predialysis potassium (mEq/L) | 0 | 4.92 ± 0.59 | 0 | 4.83 ± 0.47 | 0 | 4.99 ± 0.68 |
Predialysis calcium (mg/dL) | 0 | 9.35 ± 0.74 | 0 | 9.51 ± 0.83 | 0 | 9.22 ± 0.65 |
Predialysis hemoglobin (mg/dL) | 0 | 12.1 ± 1.3 | 0 | 12.4 ± 1 | 0 | 11.8 ± 1.4 |
Predialysis Parathyroid hormone (pg/mL) | 0 | 408 [283,927] | 0 | 389 [246,1039] | 0 | 471 [289,927] |
Physical Health Composite score | 0 | 40.3 ± 11.0 | 0 | 39.7 ± 9.6 | 0 | 40.9 ± 12.2 |
Mental Health Composite score | 0 | 47.6 ± 12.4 | 0 | 45.8 ± 10.1 | 0 | 49.1 ± 14.0 |
Iron administration (Y/N) | 0 | 1 (2%) | 0 | 1 (5%) | 0 | 0 |
Erythropoiesis-Stimulating Agents (EPO equivalent units) | 0 | 9250 [3138,22,875] | 0 | 8750 [2913,27,625] | 0 | 9250 [3138,19,750] |
Left Ventricular Mass (g) | 0 | 166 ± 65 | 0 | 179 ± 66 | 0 | 155 ± 63 |
CRP (mg/dL) | 10 | 0.362 [0.221,0.964] | 4 | 0.412 [0.242,0.986] | 6 | 0.362 [0.221,0.932] |